 |
|
2 software tools that improve identification of cancer biomarkers earn certification
August 18, 2009The explosive growth of genomic and proteomic data has ushered in a new era of molecular medicine in which cancer detection, diagnosis and treatment are tailored to each individual's molecular profile. But this personalized medicine approach requires that researchers discover and link biomarkers -- such as genes or proteins -- to specific disease behaviors, such as the rate of tumor progression and different responses to treatments.
Two new software programs that help address that challenge have recently earned silver-level compatibility certification from the National Cancer Institute's cancer Biomedical Informatics Grid®, also known as caBIG®. The programs improve the process of identifying cancer biomarkers from gene expression data.
Developed by May Dongmei Wang and her team in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, the programs -- caCORRECT and omniBioMarker -- remove noise and artifacts, and identify and validate biomarkers from microarray data. Funding to develop the programs was provided by the National Institutes of Health, the Georgia Cancer Coalition, Microsoft Research and Hewlett-Packard.
"Certification by caBIG means the tools can be easily used by everyone in the cancer community to improve approaches to cancer detection, diagnosis, treatment and prevention," said Wang, an associate professor in the Coulter Department and a Georgia Cancer Coalition Distinguished Cancer Scholar.
caBIG is a collaborative information network that enables researchers, physicians, and patients to share data, tools and knowledge to accelerate the discovery of new approaches that they hope will ultimately improve cancer patient outcomes. To become caBIG-certified, caCORRECT and omniBioMarker passed a rigorous set of requirements, ensuring the cancer research community that the software tools are high quality and interoperable with all other caBIG-certified systems for nationwide deployment.
caCORRECT -- chip artifact CORRECTion -- is a software program that improves the quality of collected microarray data, ultimately leading to improved biomarker selection. Widely used Affymetrix microarrays contain thousands of probes, each including a 25-oligo sequence, which are used to detect mRNA expression levels.
"Once someone has collected microarray data, it is important to run quality control on it and remove any problematic points of data that could highlight incorrect biomarkers when analyzed," explained Wang, who is also director of the biocomputing and bioinformatics core in the Emory-Georgia Tech National Cancer Institute Center for Cancer Nanotechnology Excellence (CCNE).
Since each microarray chip contains thousands of spots, it is easy for a few spots to become marred by artifacts and noise. These unusable portions are typically the result of experimental variations by different laboratory technicians or errors that create scratches, edge effects and bubble effects on the data.
caCORRECT removes the noise and artifacts from the data, while retaining high-quality genes on the array. The software can also effectively recover lost information that has been obscured by artifacts.
In collaboration with Andrew N. Young, an associate professor in pathology and laboratory medicine at Emory University School of Medicine and clinical laboratory director at Grady Health System, Wang and graduate students Todd Stokes, Martin Ahrens and Richard Moffitt validated the caCORRECT software. A large-scale survey of public data and data from Young's laboratory demonstrated the ability of caCORRECT to assess and improve the quality of a wide array of datasets.
"caCORRECT is a quality assurance tool that allows researchers to utilize and trust imperfect experimental microarray data that they spent a tremendous amount of time and money to generate," added Wang. "caCORRECT improves the downstream analysis of microarray data and should be used before conducting biomarker selection, therapeutic target studies, or pathway analysis studies in bioinformatics and systems biology."
Once the quality of the data is assured with caCORRECT, researchers can use the caBIG-certified omniBioMarker software to identify and validate biomarkers from the high-throughput gene expression data.
Candidate cancer biomarkers are typically genes expressed at different levels in cancer patients compared to healthy subjects. omniBioMarker searches these groups of patient data for genes with the highest potential for accurately determining whether a patient has cancer. However, because individual genes are not expressed independently, the software also identifies groups of genes that act in concert.
The advantage of the omniBioMarker software is that it fine-tunes biomarker selection to a particular dataset or clinical problem based on prior biological knowledge. It also applies unique analysis parameters for each specific clinical problem. The parameters are optimal when the software selects genes that are known to be relevant biomarkers based on clinical observations and laboratory experiments available in literature and public databases. Then the software finds new potential biomarkers for experimental validation.
Wang, graduate student John Phan and Young tested the ability of the software to identify biomarkers in clinical renal cancer microarray data. The researchers selected renal cancer for study because it has several distinct subtypes, which can appear in the same person in varying degrees and must be treated according to the diagnosed subtype to maximize treatment success. The results indicate that integrating prior laboratory and clinical knowledge with the microarray data improves biomarker selection.
"Using omniBioMarker to create an optimal metric for ranking and identifying novel biomarkers reduces the number of false discoveries, increases the number of true discoveries, reduces the required time for validation and increases the overall efficiency of the process," noted Wang.
Since receiving caBIG silver-level compatibility certification for caCORRECT and omniBioMarker, Wang and her team have been working on getting two more software programs certified -- Q-IHC, a tool that analyzes and quantifies multi-spectral images such as quantum dot-stained histopathological images, and omniVisGrid, a grid-based tool that visualizes data and analysis processes of microarrays, biological pathways and clinical outcomes.
Georgia Institute of Technology Research News
"Certification by caBIG means the tools can be easily used by everyone in the cancer community to improve approaches to cancer detection, diagnosis, treatment and prevention," said Wang, an associate professor in the Coulter Department and a Georgia Cancer Coalition Distinguished Cancer Scholar.
caBIG is a collaborative information network that enables researchers, physicians, and patients to share data, tools and knowledge to accelerate the discovery of new approaches that they hope will ultimately improve cancer patient outcomes. To become caBIG-certified, caCORRECT and omniBioMarker passed a rigorous set of requirements, ensuring the cancer research community that the software tools are high quality and interoperable with all other caBIG-certified systems for nationwide deployment.
caCORRECT -- chip artifact CORRECTion -- is a software program that improves the quality of collected microarray data, ultimately leading to improved biomarker selection. Widely used Affymetrix microarrays contain thousands of probes, each including a 25-oligo sequence, which are used to detect mRNA expression levels.
"Once someone has collected microarray data, it is important to run quality control on it and remove any problematic points of data that could highlight incorrect biomarkers when analyzed," explained Wang, who is also director of the biocomputing and bioinformatics core in the Emory-Georgia Tech National Cancer Institute Center for Cancer Nanotechnology Excellence (CCNE).
Since each microarray chip contains thousands of spots, it is easy for a few spots to become marred by artifacts and noise. These unusable portions are typically the result of experimental variations by different laboratory technicians or errors that create scratches, edge effects and bubble effects on the data.
caCORRECT removes the noise and artifacts from the data, while retaining high-quality genes on the array. The software can also effectively recover lost information that has been obscured by artifacts.
In collaboration with Andrew N. Young, an associate professor in pathology and laboratory medicine at Emory University School of Medicine and clinical laboratory director at Grady Health System, Wang and graduate students Todd Stokes, Martin Ahrens and Richard Moffitt validated the caCORRECT software. A large-scale survey of public data and data from Young's laboratory demonstrated the ability of caCORRECT to assess and improve the quality of a wide array of datasets.
"caCORRECT is a quality assurance tool that allows researchers to utilize and trust imperfect experimental microarray data that they spent a tremendous amount of time and money to generate," added Wang. "caCORRECT improves the downstream analysis of microarray data and should be used before conducting biomarker selection, therapeutic target studies, or pathway analysis studies in bioinformatics and systems biology."
Once the quality of the data is assured with caCORRECT, researchers can use the caBIG-certified omniBioMarker software to identify and validate biomarkers from the high-throughput gene expression data.
Candidate cancer biomarkers are typically genes expressed at different levels in cancer patients compared to healthy subjects. omniBioMarker searches these groups of patient data for genes with the highest potential for accurately determining whether a patient has cancer. However, because individual genes are not expressed independently, the software also identifies groups of genes that act in concert.
The advantage of the omniBioMarker software is that it fine-tunes biomarker selection to a particular dataset or clinical problem based on prior biological knowledge. It also applies unique analysis parameters for each specific clinical problem. The parameters are optimal when the software selects genes that are known to be relevant biomarkers based on clinical observations and laboratory experiments available in literature and public databases. Then the software finds new potential biomarkers for experimental validation.
Wang, graduate student John Phan and Young tested the ability of the software to identify biomarkers in clinical renal cancer microarray data. The researchers selected renal cancer for study because it has several distinct subtypes, which can appear in the same person in varying degrees and must be treated according to the diagnosed subtype to maximize treatment success. The results indicate that integrating prior laboratory and clinical knowledge with the microarray data improves biomarker selection.
"Using omniBioMarker to create an optimal metric for ranking and identifying novel biomarkers reduces the number of false discoveries, increases the number of true discoveries, reduces the required time for validation and increases the overall efficiency of the process," noted Wang.
Since receiving caBIG silver-level compatibility certification for caCORRECT and omniBioMarker, Wang and her team have been working on getting two more software programs certified -- Q-IHC, a tool that analyzes and quantifies multi-spectral images such as quantum dot-stained histopathological images, and omniVisGrid, a grid-based tool that visualizes data and analysis processes of microarrays, biological pathways and clinical outcomes.
Georgia Institute of Technology Research News
Biomarkers Current Events and Biomarkers News RSSSaliva proteins change as women age
In a step toward using human saliva to tell whether those stiff joints, memory lapses, and other telltale signs of aging are normal or red flags for disease, scientists are describing how the protein content of women's saliva change with advancing age.
Elevated biomarkers lead to diminished quality of life in heart attack patients post-discharge
Many heart attack patients have high levels of cardiac biomarkers in the blood for several months after leaving the hospital, with more shortness of breath and chest pain, according to a Henry Ford Hospital study.
Largest-ever database for liver proteins may lead to treatments for hepatitis
Scientists at a group of 11 research centers in China are reporting for the first time assembly of the largest-ever collection of data about the proteins produced by genes in a single human organ.
Neuroimaging provides insights into new treatment options for Alzheimer's disease
With about 35 million people around the world suffering from Alzheimer's disease (AD) by the year 2010 and an expectation that these numbers will double every twenty years with approximately 115 million cases by 2050, pressure on healthcare systems worldwide will be intense.
Expectant moms, babies subjects of new Singapore study to prevent obesity and diabetes in adults
Three Singapore biomedical institutions have launched a major, long-term study of pregnant mothers and their fetuses as well as infant children to determine just how profoundly environmental factors early in life influence the onset of diseases such as obesity and diabetes in later years.
New finding suggests prostate biopsy is not always necessary
Researchers at Wake Forest University School of Medicine and the University of Wisconsin-Madison have discovered that some elevated prostate-specific antigen (PSA) levels in men may be caused by a hormone normally occurring in the body, and are not necessarily a predictor of the need for a prostate biopsy.
Scientists uncover new key to the puzzle of hormone therapy and breast cancer
The use of postmenopausal hormone therapy has decreased over time in the United States, which researchers suggest may play a key role in the declining rate of atypical ductal hyperplasia, a known risk factor for breast cancer.
New Notre Dame study provides insights into the molecular basis of tumor cell behavior
A new study by a team of researchers led by Crislyn D'Souza-Schorey, associate professor of biological sciences at the University of Notre Dame, sheds light on the molecular basis by which tumor cells modulate their surroundings to favor cancer progression.
Does green tea prevent cancer? Evidence continues to brew, but questions remain
Although scientists are reluctant to officially endorse green tea as a cancer prevention method, evidence continues to grow about its protective effects, including results of a new study published in Cancer Prevention Research, a journal of the American Association for Cancer Research, which suggests some reduction in oral cancer.
Green tea shows promise as chemoprevention agent for oral cancer, M. D. Anderson study finds
Green tea extract has shown promise as cancer prevention agent for oral cancer in patients with a pre-malignant condition known as oral leukoplakia, according to researchers at The University of Texas M. D. Anderson Cancer Center.
More Biomarkers Current Events and Biomarkers News Articles
 |
Biomarkers: The 10 Keys to Prolonging Vitality by William Evans (Author) Exciting new evidence from the USDA Human Nutrition Research Center on Aging at Tufts University has demonstrated that the body's decline is due not to the passing of years but to the combined effects of inactivity, poor nutrition, and illness -- much of which can be controlled. This breakthrough study shows that regardless of your age or present physical condition, the aging process can be slowed -- or even reversed! The authors have identified ten "biomarkers," the key physiological factors associated with prolonged youth and vitality: * lean body (muscle) mass |
 |
Biomarkers: 10 Determinants of Aging You Can Control by William Evans (Author), Irwin Rosenberg (Author) |
|
Cancer Biomarkers by Ios Press Original research findings (and reviews solicited by the Editor) on the subject of the identification of markers associated with the disease processes whether or not they are an integral part of the pathological lesion. | |
 |
Biomarkers of Disease: An Evidence-Based Approach by Andrew K. Trull (Editor), Lawrence M. Demers (Editor), David W. Holt (Editor), Atholl Johnston (Editor), J. Michael Tredger (Editor), Christopher P. Price (Editor) This new publication takes a critical, evidence-based look at the efficacy of new diagnostic tests which are increasingly being used to evaluate organ damage and dysfunction. The use of biomarkers is growing, with a steady stream of new products being brought out by the pharmaceutical industry. However, in many cases the evidence which supports the use of these new methods as opposed to traditional biochemical tests has not yet been demonstrated, and it is intended that this volume will help clarify the strengths and weaknesses of using these biomarkers across a wide range of applications and in the various organs of the body. This approach will provide an invaluable overview of the diverse applications of biomarkers in medicine. |
 |
Biomarker Methods in Drug Discovery and Development (Methods in Pharmacology and Toxicology) by Feng Wang (Editor) Within the pharmaceutical industry, the improvement of drug discovery and development efficiency and the expected personalization of medicine have become vitally important issues. In Biomarker Methods in Drug Discovery and Development, expert researchers provide a tool box for those who have a general interest in biomarker research and for those currently specializing in certain technologies but desiring an understanding of other available methodologies. Its chapters include validated, mature methods as well as new, incredibly promising protocols which aim to apply multiple technologies at different molecular levels in order to surmount the monumental and complex task of transforming the pharmaceutical research and development processes. As a volume in the Methods in Pharmacology and... |
 |
Biomarkers by S.V.S. Rana (Author), Sung-Eun Lee (Author) |
 |
Cancer Biomarkers: Analytical Techniques for Discovery (Wiley - Interscience Series on Mass Spectrometry) by Mahmoud H. Hamdan (Author), Dominic M. Desiderio (Series Editor), Nico M. Nibbering (Series Editor) Tools, techniques, and progress in cancer biomarkers discovery The completion of a number of gene sequencing projects, recent advances in genomic and proteomic technologies, and the availability of powerful bioinformatics tools have led to promising new avenues and approaches in the search for cancer biomarkers. This book provides a comprehensive overview of current methodologies and technologies. It discusses biomarker discovery as a whole, rather than focusing on one specific marker or cancer. With information on both existing and potential biomarkers, Cancer Biomarkers: Analytical Techniques for Discovery: * Provides insights into the current technological platforms for biomarker discovery, including mass spectrometry combined with multidimensional chromatography,... |
 |
The Biomarker Guide: Volume 2, Biomarkers and Isotopes in Petroleum Systems and Earth History by K. E. Peters (Author), C. C. Walters (Author), J. M. Moldowan (Author) The second volume itemizes parameters used to genetically correlate petroleum and interpret thermal maturity and extent of biodegradation. It documents most known petroleum systems by geologic age throughout Earth history. |
 |
The Biomarker Guide: Volume 1, Biomarkers and Isotopes in the Environment and Human History (v. 1) by K. E. Peters (Author), C. C. Walters (Author), J. M. Moldowan (Author) Biomarkers are compounds found in crude oil with structures inherited from once-living organisms. They persist in oil spills, refinery products and archaeological artifacts, and can be used to identify the origin, geological age and environmental conditions prevalent during their formation and alteration. These two volumes will be an invaluable resource for geologists, petroleum geochemists, biogeochemists, environmental and forensic scientists, natural product chemists and archaeologists. The first of two volumes of The Biomarker Guide discusses the origins of biomarkers and introduces basic chemical principles relevant to their study. It goes on to discuss analytical techniques, and the applications of biomarkers in environmental and archaeological problems. |
 |
Cardiac Biomarkers in Clinical Practice by James Januzzi (Author) Cardiac Biomarkers in Clinical Practice presents a case based approach to biomarkers in heart diseases including heart failure, ischemic heart disease, and outpatient. Divided into six sections, this book provides physicians and other health care providers with a clear understanding of the role of biomarkers in clinical cardiovascular medicine. |
| © 2009 BrightSurf.com |